Detalles de la búsqueda
1.
Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.
Circulation
; 147(22): 1670-1683, 2023 05 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37039015
2.
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
Lancet
; 402(10416): 2004-2017, 2023 11 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37931629
3.
Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.
Nephrol Dial Transplant
; 39(3): 414-425, 2024 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37632201
4.
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.
Cardiovasc Diabetol
; 22(1): 330, 2023 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38017482
5.
The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan.
Nephrol Dial Transplant
; 38(10): 2289-2297, 2023 09 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37102226
6.
Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19.
J Mol Cell Cardiol
; 167: 92-96, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35339512
7.
Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.
Diabetes Obes Metab
; 24(8): 1578-1587, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35478433
8.
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
Circulation
; 142(11): 1040-1054, 2020 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32673497
9.
The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure.
J Card Fail
; 27(12): 1447-1455, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34289398
10.
Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials.
Diabetes Obes Metab
; 23(8): 1961-1967, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33908683
11.
Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19.
Pulm Pharmacol Ther
; 69: 102035, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33933611
12.
Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial.
J Pharmacol Exp Ther
; 375(1): 76-91, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32764153
13.
Novel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitium.
Nephrol Dial Transplant
; 35(12): 2059-2072, 2020 12 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32853351
14.
A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes.
Diabetes Obes Metab
; 22(7): 1157-1166, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32115853
15.
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
JAMA
; 323(14): 1353-1368, 2020 04 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32219386
16.
Development of Human Target Validation Classification that Predicts Future Clinical Efficacy.
J Pharmacol Exp Ther
; 368(2): 255-261, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30482795
17.
The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia.
Nephrol Dial Transplant
; 34(2): 339-346, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29617976
18.
Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.
Diabetes Obes Metab
; 21(12): 2667-2673, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31407856
19.
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
Diabetes Obes Metab
; 21(12): 2684-2693, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31423699
20.
Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
Am J Physiol Renal Physiol
; 315(5): F1295-F1306, 2018 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30019930